Snvia
1 known investors
SNVIA is a South Korean Pusan National University spin-off developing embeddable microneedle patches and therapeutic polymers.
Also known as SNVIA · Snvia Co., Ltd.
Investors · 1
Company profile
researched Aug 2026SNVIA is a South Korean medical products developer working on local drug delivery and regenerative medicine. Its core platform is an embeddable microneedle technology intended to deliver drugs through the skin, which the company describes as avoiding risks of infection or bleeding associated with conventional delivery. Reported microneedle attributes include swellable and embeddable needles and controlled release of payloads.
Alongside microneedles, the company operates a therapeutic polymer platform covering tissue adhesion applications such as surgical glue and medical sealant, and a methacrylated hyaluronic acid material (HAMA). The company both develops and manufactures medical microneedle products based on these platforms.
Founding story
SNVIA is a subsidiary of the technology holdings company of Pusan National University (PNU) in South Korea, and is listed as founded in 2016.
Business model
SNVIA develops and manufactures medical products, specifically microneedle patches and therapeutic polymer materials for local drug delivery and regenerative medicine applications.
Latest developments
Corporate notices on the company website reference a 2025 extraordinary general meeting of shareholders and a third-party allotment share issuance notice.
▸Full profile — market position, technology, geography, history
Market position
SNVIA operates in the microneedle drug delivery field, where other South Korean developers include the publicly traded Raphas, QuadMedicine, and JUVIC, alongside international players such as Pharma Latch (Ireland), Novinject (Belgium), and Microdermics (Canada).
The company positions its embeddable microneedle platform as a first-of-its-kind medical microneedle system for transdermal drug delivery without infection or bleeding risk, combined with an in-house therapeutic polymer platform for tissue adhesion products.
Technology
The company's embeddable microneedle platform is described as a medical microneedle system enabling delivery of drugs through the skin without risk of infection or bleeding, with swellable and embeddable needle designs and controlled-release capability. A separate therapeutic polymer platform addresses tissue adhesion and includes surgical glue, medical sealant, and a new methacrylated hyaluronic acid (HAMA) material.
Geography
The company is based in South Korea.
History
The company was established in 2016 as a subsidiary of the Pusan National University technology holdings company and has since focused on embeddable microneedle and therapeutic polymer product development. Corporate notices published on its website include a third-party allotment new share issuance notice, a notice convening the first extraordinary general meeting of shareholders in 2025, and a notice convening the 10th annual general meeting of shareholders.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 3
primary sources listed
- SNviasnvia.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Snvia do?
- SNVIA is a South Korean Pusan National University spin-off developing embeddable microneedle patches and therapeutic polymers.
- Who are Snvia's investors?
- Snvia's investors include Colopl Next.